Table of content
Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.2 Market Definitions/Scope
1.3 Information Procurement
1.3.1 Information analysis
1.3.2 Market formulation & data visualization
1.3.3 Data validation & publishing
1.4 Research Scope and Assumptions
1.4.1 List to Data Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Clinical Trial Equipment & Ancillary Solutions Market Variables and Trends
3.1 Market Lineage Outlook
3.2 Market Dynamics
3.2.1 Market Driver Impact Analysis
3.2.1.1 Evolving Clinical Trials Needs
3.2.1.2 Rising Investment in R&D
3.2.1.3 Growing pharmaceutical & Medical Devices industry
3.2.2 Market Restraint Impact Analysis
3.2.2.1 Rising Cost of Clinical Trials
3.3 Porter’s Five Forces Analysis
3.4 PEST Analysis
3.5 Major Deals & Strategic Alliances Analysis
3.6 COVID Impact Analysis
3.7 Revenues of Major Companies in Clinical Trial Equipment & Ancillary Solutions (overall revenue)
3.8 Revenue Split Analysis by Product Segment for Major Companies (High to Low)
Chapter 4 Clinical Trial Equipment & Ancillary Solutions Market: Product Estimates & Trend Analysis
4.1 Product Movement Analysis & Market Share, 2022 & 2030
4.2 Clinical Trial Equipment & Ancillary Solutions Market Estimates & Forecast, By Product (USD Million)
4.2.1 Sourcing
4.2.1.1 Procurement
4.2.1.1.1 Equipment
4.2.1.1.2 Ancillaries
4.2.1.2 Rental
4.2.1.2.1 Equipment
4.2.1.2.2 Ancillaries
4.2.2 Supply/Logistics
4.2.2.1 Transportation
4.2.2.2 Packaging
4.2.2.3 Others
4.2.3 Service
4.2.3.1 Calibrations
4.2.3.2 Equipment Servicing
4.2.3.3 Others
4.2.4 Others
Chapter 5 Clinical Trial Equipment & Ancillary Solutions Market: Phase Estimates & Trend Analysis
5.1 Phase Movement Analysis & Market Share, 2022 & 2030
5.2 Clinical Trial Equipment & Ancillary Solutions Market Estimates & Forecast, By Phase (USD Million)
5.2.1 Phase I
5.2.2 Phase II
5.2.3 Phase III
5.2.4 Phase IV
Chapter 6 Clinical Trial Equipment & Ancillary Solutions Market: Regional Analysis
6.1 Clinical Trial Equipment & Ancillary Solutions Market: Regional Outlook
6.2 North America
6.2.1 North America Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.2.2 U.S.
6.2.2.1 Key Country Dynamics
6.2.2.2 U.S. Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.2.2.3 Regulatory Scenario
6.2.3 Canada
6.2.3.1 Key Country Dynamics
6.2.3.2 Canada Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.2.3.3 Regulatory Scenario
6.3 Europe
6.3.1 Europe Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.3.2 UK
6.3.2.1 Key Country Dynamics
6.3.2.2 UK Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.3.2.3 Regulatory Scenario
6.3.3 Germany
6.3.3.1 Key Country Dynamics
6.3.3.2 Germany Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.3.3.3 Regulatory Scenario
6.3.4 France
6.3.4.1 Key Country Dynamics
6.3.4.2 France Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.3.4.3 Regulatory Scenario
6.3.5 Italy
6.3.5.1 Key Country Dynamics
6.3.5.2 Italy Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.3.5.3 Regulatory Scenario
6.3.6 Spain
6.3.6.1 Key Country Dynamics
6.3.6.2 Spain Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.3.6.3 Regulatory Scenario
6.3.7 Denmark
6.3.7.1 Key Country Dynamics
6.3.7.2 Denmark Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.3.7.3 Regulatory Scenario
6.3.8 Sweden
6.3.8.1 Key Country Dynamics
6.3.8.2 Sweden Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.3.8.3 Regulatory Scenario
6.3.9 Norway
6.3.9.1 Key Country Dynamics
6.3.9.2 Norway Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.3.9.3 Regulatory Scenario
6.4 Asia Pacific
6.4.1 Asia Pacific Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.4.2 Japan
6.4.2.1 Key Country Dynamics
6.4.2.2 Japan Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.4.2.3 Regulatory Scenario
6.4.3 China
6.4.3.1 Key Country Dynamics
6.4.3.2 China Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.4.3.3 Regulatory Scenario
6.4.4 India
6.4.4.1 Key Country Dynamics
6.4.4.2 India Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.4.4.3 Regulatory Scenario
6.4.5 Australia
6.4.5.1 Key Country Dynamics
6.4.5.2 Australia Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.4.5.3 Regulatory Scenario
6.4.6 Thailand
6.4.6.1 Key Country Dynamics
6.4.6.2 Thailand Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.4.6.3 Regulatory Scenario
6.4.7 South Korea
6.4.7.1 Key Country Dynamics
6.4.7.2 South Korea Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.4.7.3 Regulatory Scenario
6.5 Latin America
6.5.1 Latin America Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.5.2 Brazil
6.5.2.1 Key Country Dynamics
6.5.2.2 Brazil Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.5.2.3 Regulatory Scenario
6.5.3 Mexico
6.5.3.1 Key Country Dynamics
6.5.3.2 Mexico Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.5.3.3 Regulatory Scenario
6.5.4 Argentina
6.5.4.1 Key Country Dynamics
6.5.4.2 Argentina Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.5.4.3 Regulatory Scenario
6.5.5 Colombia
6.5.5.1 Colombia Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.5.5.2 Regulatory Scenario
6.6 MEA
6.6.1 MEA Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.6.2 South Africa
6.6.2.1 Key Country Dynamics
6.6.2.2 South Africa Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.6.2.3 Regulatory Scenario
6.6.3 Saudi Arabia
6.6.3.1 Key Country Dynamics
6.6.3.2 Saudi Arabia Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.6.3.3 Regulatory Scenario
6.6.4 UAE
6.6.4.1 Key Country Dynamics
6.6.4.2 UAE Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.6.4.3 Regulatory Scenario
6.6.5 Kuwait
6.6.5.1 Key Country Dynamics
6.6.5.2 Kuwait Clinical Trial Equipment & Ancillary Solutions market, 2018 – 2030 (USD Million)
6.6.5.3 Regulatory Scenario
Chapter 7 Competitive Landscape
7.1 Company Categorization
7.2 Strategy Mapping
7.3 Company Profiles/Listing
7.4 Ancillare LP
7.4.1 Overview
7.4.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.3 Service Benchmarking
7.4.4 Strategic Initiatives
7.4.5 Imperial CRS
7.4.5.1 Overview
7.4.5.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.5.3 Service Benchmarking
7.4.5.4 Strategic Initiatives
7.4.6 Woodley Equipment Company Ltd
7.4.6.1 Overview
7.4.6.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.6.3 Service Benchmarking
7.4.6.4 Strategic Initiatives
7.4.7 Thermo Fisher Scientific Inc
7.4.7.1 Overview
7.4.7.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.7.3 Service Benchmarking
7.4.7.4 Strategic Initiatives
7.4.8 Parexel International Corporation
7.4.8.1 Overview
7.4.8.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.8.3 Service Benchmarking
7.4.8.4 Strategic Initiatives
7.4.9 Emsere (Medicapital Rent)
7.4.9.1 Overview
7.4.9.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.9.3 Service Benchmarking
7.4.9.4 Strategic Initiatives
7.4.10 Quipment SAS
7.4.10.1 Overview
7.4.10.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.10.3 Service Benchmarking
7.4.10.4 Strategic Initiatives
7.4.11 IRM
7.4.11.1 Overview
7.4.11.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.11.3 Service Benchmarking
7.4.11.4 Strategic Initiatives
7.4.12 Marken A UPS Company
7.4.12.1 Overview
7.4.12.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.12.3 Service Benchmarking
7.4.12.4 Strategic Initiatives
7.4.13 Myonex
7.4.13.1 Overview
7.4.13.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.13.3 Service Benchmarking
7.4.13.4 Strategic Initiatives
7.4.14 Yourway
7.4.14.1 Overview
7.4.14.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.14.3 Service Benchmarking
7.4.14.4 Strategic Initiatives
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/